Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: J Neuroendocrinol. 2009 Oct 14;21(12):1038–1044. doi: 10.1111/j.1365-2826.2009.01927.x

Table 2.

Impact of OVX and surgical treatment on animal body weight: Animals gained significant body weight between OVX and cannula insertion. Although animals lost weight after ischemia, this weight stabilized by the time of perfusion.

Treatment Group Weight 1 (g) Weight 2 (g) Weight 3 (g) Weight 4 (g) Weight 5 (g)
Vehicle (n=13) 374.1 ± 69.2 469.8 ± 83.4* 435.1 ± 80.7** 413.8 ± 84.4*** 420.0 ± 67.4
Oestradiol (n=10) 396.7 ± 56.5 477.6 ± 69.6* 431.1 ± 67.8** 412.1 ± 69.1*** 399.8 ± 66.0
IGF1 (n=12) 388.1 ± 45.5 477.3 ± 48.2* 439.7 ± 46.5** 416.1 ± 43.7*** 417.1 ± 42.7
Oestradiol + IGF1 (n=8) 381.8 ± 38.7 463.6 ± 41.0* 431.9 ± 38.4** 401.5 ± 35.1*** 394.1 ± 15.3
Sham (n=10) 381.8 ± 67.8 447.9 ± 70.6* 428.2 ± 62.7** 400.6 ± 64.7*** 403.5 ± 59.5

Values represent mean body weight (g) ± S.D at the time of OVX (Weight 1), cannula/pellet insertion (Weight 2), Stage 1 (Weight 3) and Stage 2 (Weight 4) of ischemia, and at the time of perfusion (Weight 5).

*

p<0.001 vs Weight 1;

**

p<0.001 vs Weight 2;

***

p<0.001 vs Weight 3.

Some animals were not weighed at the time of perfusion and therefore could not be included in the repeated measures analysis.